Cargando…
Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
The aim of this study was to establish whether a universal pneumococcal vaccination for older adults in Norway is likely to be cost-effective from the perspective of the health care provider. A decision tree model developed by the Public Health Agency of Sweden was adopted to the Norwegian setting....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746426/ https://www.ncbi.nlm.nih.gov/pubmed/35917277 http://dx.doi.org/10.1080/21645515.2022.2101333 |
_version_ | 1784849356793315328 |
---|---|
author | Nymark, Liv Solvår Dag Berild, Jacob Lyngstad, Trude Marie Askeland Winje, Brita Frimann Vestrheim, Didrik Aaberge, Ingeborg Juvet, Lene Kristine Wolff, Ellen |
author_facet | Nymark, Liv Solvår Dag Berild, Jacob Lyngstad, Trude Marie Askeland Winje, Brita Frimann Vestrheim, Didrik Aaberge, Ingeborg Juvet, Lene Kristine Wolff, Ellen |
author_sort | Nymark, Liv Solvår |
collection | PubMed |
description | The aim of this study was to establish whether a universal pneumococcal vaccination for older adults in Norway is likely to be cost-effective from the perspective of the health care provider. A decision tree model developed by the Public Health Agency of Sweden was adopted to the Norwegian setting. Two cohorts, consisting of 65-year-olds and 75-year-olds grouped into vaccinated and unvaccinated, were followed over a 5-year time horizon. In the base case, the 23-valent polysaccharide vaccine (PPV23) was used while the 13-valent pneumococcal conjugate vaccine (PCV13) was included in scenario analyses only. The costs and health benefits (measured in quality adjusted life years (QALY) gained) were compared in the two cohorts between the vaccinated and unvaccinated groups. The impact of indirect effects of the vaccine, such as herd immunity and serotype replacement, were not investigated. The relative importance of change in price was assessed by performing one-way sensitivity analyses. Under base-case assumptions, the programme for the 75-year-old cohort is expected to be cost-effective from the health care perspective at the current pharmacy purchasing price and at 75% vaccination coverage as it falls below the lower end of the cost-effectiveness threshold range (NOK 9467/EUR 964). In comparison, for the 65-year-old cohort the cost per QALY gained is approximately NOK 780 206 (EUR 79 451) under the base-case assumptions which falls within the acceptable ranges in a Norwegian context for both the 65- and 75-year-old cohorts. There is no exact cost-effectiveness threshold in Norway. However, introducing a vaccination programme against pneumococcal disease for 65-year-olds and 75-year-olds in Norway is likely to fall within the acceptable cost-effectiveness threshold range. |
format | Online Article Text |
id | pubmed-9746426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-97464262022-12-14 Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway Nymark, Liv Solvår Dag Berild, Jacob Lyngstad, Trude Marie Askeland Winje, Brita Frimann Vestrheim, Didrik Aaberge, Ingeborg Juvet, Lene Kristine Wolff, Ellen Hum Vaccin Immunother Pneumococcal – Research Article The aim of this study was to establish whether a universal pneumococcal vaccination for older adults in Norway is likely to be cost-effective from the perspective of the health care provider. A decision tree model developed by the Public Health Agency of Sweden was adopted to the Norwegian setting. Two cohorts, consisting of 65-year-olds and 75-year-olds grouped into vaccinated and unvaccinated, were followed over a 5-year time horizon. In the base case, the 23-valent polysaccharide vaccine (PPV23) was used while the 13-valent pneumococcal conjugate vaccine (PCV13) was included in scenario analyses only. The costs and health benefits (measured in quality adjusted life years (QALY) gained) were compared in the two cohorts between the vaccinated and unvaccinated groups. The impact of indirect effects of the vaccine, such as herd immunity and serotype replacement, were not investigated. The relative importance of change in price was assessed by performing one-way sensitivity analyses. Under base-case assumptions, the programme for the 75-year-old cohort is expected to be cost-effective from the health care perspective at the current pharmacy purchasing price and at 75% vaccination coverage as it falls below the lower end of the cost-effectiveness threshold range (NOK 9467/EUR 964). In comparison, for the 65-year-old cohort the cost per QALY gained is approximately NOK 780 206 (EUR 79 451) under the base-case assumptions which falls within the acceptable ranges in a Norwegian context for both the 65- and 75-year-old cohorts. There is no exact cost-effectiveness threshold in Norway. However, introducing a vaccination programme against pneumococcal disease for 65-year-olds and 75-year-olds in Norway is likely to fall within the acceptable cost-effectiveness threshold range. Taylor & Francis 2022-08-02 /pmc/articles/PMC9746426/ /pubmed/35917277 http://dx.doi.org/10.1080/21645515.2022.2101333 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Pneumococcal – Research Article Nymark, Liv Solvår Dag Berild, Jacob Lyngstad, Trude Marie Askeland Winje, Brita Frimann Vestrheim, Didrik Aaberge, Ingeborg Juvet, Lene Kristine Wolff, Ellen Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway |
title | Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway |
title_full | Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway |
title_fullStr | Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway |
title_full_unstemmed | Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway |
title_short | Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway |
title_sort | cost-utility analysis of a universal pneumococcal vaccination programme for older adults in norway |
topic | Pneumococcal – Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746426/ https://www.ncbi.nlm.nih.gov/pubmed/35917277 http://dx.doi.org/10.1080/21645515.2022.2101333 |
work_keys_str_mv | AT nymarklivsolvar costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway AT dagberildjacob costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway AT lyngstadtrudemarie costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway AT askelandwinjebrita costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway AT frimannvestrheimdidrik costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway AT aabergeingeborg costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway AT juvetlenekristine costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway AT wolffellen costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway |